Home › Funds › Potomac Capital Management, Inc. › GANX

Potomac Capital Management, Inc. position in GANX

GAIN THERAPEUTICS INC · Health Care

Potomac Capital Management, Inc. reported holding 930,000 shares of GANX (GAIN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.6M, representing 1.40% of its reported portfolio and ranking #21 among its reported holdings. Potomac Capital Management, Inc. has disclosed GANX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)930.00K sh
Reported value held$1.61M
Portfolio Weight1.40%
First reportedQ4 2025
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Potomac Capital Management, Inc.'s GANX position evolved

Potomac Capital Management, Inc. first disclosed a stake in GANX in Q4 2025 at 1,010,000 shares (US$3.3M). Across 4 filings, Potomac Capital Management, Inc. increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 930,000 shares valued at US$1.6M — a reduction of -16,400 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2025 1.01M $3.25M New
Q1 2026 1.01M $1.96M Hold
Q2 2026 946.40K $1.92M Reduce
Q3 2026 930.00K $1.61M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GANX and 13F data

GANX (GAIN THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in GANX — the largest reported positions include DME Capital Management, LP (US$1.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GANX

All GANX fund holders →

FAQ

How long has Potomac Capital Management, Inc. held GANX?

Potomac Capital Management, Inc. has disclosed GANX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Potomac Capital Management, Inc.'s current position in GANX?

As of Q3 2026, Potomac Capital Management, Inc. holds 930.00K shares of GANX (GAIN THERAPEUTICS INC), valued at $1.61M, representing 1.40% of its reported portfolio and ranking #21.

Has Potomac Capital Management, Inc. been buying or selling GANX?

In the latest 13F filing (Q3 2026), Potomac Capital Management, Inc. reduced its position in GANX.

Which other funds hold GANX?

Other major institutional holders of GANX include DME Capital Management, LP, among 37 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.